Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma. NICE technology appraisal guidance 661
National Institute for Health and Care Excellence (NICE)
Record ID 32018011707
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta661
Year Published:
2020
URL for published report:
https://www.nice.org.uk/guidance/ta661
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Squamous Cell Carcinoma of Head and Neck
- Head and Neck Neoplasms
- Antibodies, Monoclonal, Humanized
- Immune Checkpoint Inhibitors
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.